FDA takes on COVID-19, plus ASCO’s breakthroughs: a BioCentury podcast
The latest edition of the BioCentury This Week PODCAST covers a lot of ground -- from the new roles FDA’s Janet Woodcock and Peter Marks are taking on in the race to develop COVID-19 countermeasures, to the most important breakthroughs at this year’s ASCO meeting and what BioCentury’s latest survey says about the evolution of the workplace as biopharmas start to bring employees back.
It’s hard to imagine anyone more qualified to lead the therapeutics portion of Operation Warp Speed than Woodcock, says Washington Editor Steve Usdin, noting the longtime CDER director’s deep experience with drug development, master protocol trials and manufacturing. Meanwhile, Marks will tackle thorny regulatory issues related to vaccines. Usdin also discusses why the success of any vaccine hinges on properly setting public expectations for how it will work and when it will be available. He digs into both subjects in greater detail via his article on Woodcock and Marks and a commentary on vaccines (see “Woodcock Steps Away from CDER” and “The Missing Dimension in COVID-19 Vaccine Development”)...